BACKGROUND: Redo-Surgical Aortic Valve Replacement (Redo-SAVR) and Valve-in-Valve Transcatheter Aortic Valve Implantation (ViV-TAVI) are two primary strategies for managing failure of bioprosthetic aortic valves. This appears to be of increasing concern due to the growing use of bioprostheses, even in the youngest. ViV-TAVI has been associated with improved perioperative safety compared with Redo-SAVR, but long-term outcomes remain uncertain. We therefore conducted a retrospective single-center study to compare the outcomes of the two procedures at our Institution. METHODS: We included all patients treated for aortic surgical bioprosthesis dysfunction by either Redo-SAVR or ViV-TAVI between 2015 and 2025. The primary endpoint was 1, 3, 5 and 8-year all-cause mortality. Secondary endpoints were major adverse cardiovascular events (MACE) and cardiac re-hospitalization. Propensity score matching was performed to account for the non-randomized allocation of treatment, then Cox regression and Kaplan-Meier curves were used for both primary and secondary endpoints. RESULTS: 58 Redo-SAVR and 103 ViV-TAVI patients were included. VIV-TAVI patients were older, more comorbid and had higher STS-PROM scores, with an STS-PROM cut-off of 2.62% for mortality being the most discriminative parameter between the two groups. Even if survival and freedom from cardiac rehospitalization were significantly higher in Redo-SAVR in the unmatched analysis, the propensity-score-matched survival curves showed comparable survival during the first years of follow-up and a long-term survival advantage of Redo-SAVR emerging beyond 5.8 years (HR 1.31, 95%CI 0.61–2.82). Freedom from MACE and cardiac rehospitalization were comparable. Post-operative prosthesis-patient mismatch (PPM) was however found to be significantly higher in VIV-TAVI both in the unmatched (p < 0.001) and matched cohorts (p = 0.008). CONCLUSIONS: Redo-SAVR and ViV-TAVI are both valuable strategies for failure of bioprosthetic aortic valves, with comparable results in terms of survival and adverse events when patients’ selection is solid. Yet, resulting PPM differs greatly after the two procedures and should be central in the patient allocation process.

BACKGROUND: Redo-Surgical Aortic Valve Replacement (Redo-SAVR) and Valve-in-Valve Transcatheter Aortic Valve Implantation (ViV-TAVI) are two primary strategies for managing failure of bioprosthetic aortic valves. This appears to be of increasing concern due to the growing use of bioprostheses, even in the youngest. ViV-TAVI has been associated with improved perioperative safety compared with Redo-SAVR, but long-term outcomes remain uncertain. We therefore conducted a retrospective single-center study to compare the outcomes of the two procedures at our Institution. METHODS: We included all patients treated for aortic surgical bioprosthesis dysfunction by either Redo-SAVR or ViV-TAVI between 2015 and 2025. The primary endpoint was 1, 3, 5 and 8-year all-cause mortality. Secondary endpoints were major adverse cardiovascular events (MACE) and cardiac re-hospitalization. Propensity score matching was performed to account for the non-randomized allocation of treatment, then Cox regression and Kaplan-Meier curves were used for both primary and secondary endpoints. RESULTS: 58 Redo-SAVR and 103 ViV-TAVI patients were included. VIV-TAVI patients were older, more comorbid and had higher STS-PROM scores, with an STS-PROM cut-off of 2.62% for mortality being the most discriminative parameter between the two groups. Even if survival and freedom from cardiac rehospitalization were significantly higher in Redo-SAVR in the unmatched analysis, the propensity-score-matched survival curves showed comparable survival during the first years of follow-up and a long-term survival advantage of Redo-SAVR emerging beyond 5.8 years (HR 1.31, 95%CI 0.61–2.82). Freedom from MACE and cardiac rehospitalization were comparable. Post-operative prosthesis-patient mismatch (PPM) was however found to be significantly higher in VIV-TAVI both in the unmatched (p < 0.001) and matched cohorts (p = 0.008). CONCLUSIONS: Redo-SAVR and ViV-TAVI are both valuable strategies for failure of bioprosthetic aortic valves, with comparable results in terms of survival and adverse events when patients’ selection is solid. Yet, resulting PPM differs greatly after the two procedures and should be central in the patient allocation process.

Outcomes and Patients Selection Criteria in Redo-Surgical Aortic Valve Replacement versus Valve-in-Valve Transcatheter Aortic Valve Implantation for Degenerated Bioprosthetic Valves: A Retrospective Single-Center Study.

GUERRA, GIULIA
2024/2025

Abstract

BACKGROUND: Redo-Surgical Aortic Valve Replacement (Redo-SAVR) and Valve-in-Valve Transcatheter Aortic Valve Implantation (ViV-TAVI) are two primary strategies for managing failure of bioprosthetic aortic valves. This appears to be of increasing concern due to the growing use of bioprostheses, even in the youngest. ViV-TAVI has been associated with improved perioperative safety compared with Redo-SAVR, but long-term outcomes remain uncertain. We therefore conducted a retrospective single-center study to compare the outcomes of the two procedures at our Institution. METHODS: We included all patients treated for aortic surgical bioprosthesis dysfunction by either Redo-SAVR or ViV-TAVI between 2015 and 2025. The primary endpoint was 1, 3, 5 and 8-year all-cause mortality. Secondary endpoints were major adverse cardiovascular events (MACE) and cardiac re-hospitalization. Propensity score matching was performed to account for the non-randomized allocation of treatment, then Cox regression and Kaplan-Meier curves were used for both primary and secondary endpoints. RESULTS: 58 Redo-SAVR and 103 ViV-TAVI patients were included. VIV-TAVI patients were older, more comorbid and had higher STS-PROM scores, with an STS-PROM cut-off of 2.62% for mortality being the most discriminative parameter between the two groups. Even if survival and freedom from cardiac rehospitalization were significantly higher in Redo-SAVR in the unmatched analysis, the propensity-score-matched survival curves showed comparable survival during the first years of follow-up and a long-term survival advantage of Redo-SAVR emerging beyond 5.8 years (HR 1.31, 95%CI 0.61–2.82). Freedom from MACE and cardiac rehospitalization were comparable. Post-operative prosthesis-patient mismatch (PPM) was however found to be significantly higher in VIV-TAVI both in the unmatched (p < 0.001) and matched cohorts (p = 0.008). CONCLUSIONS: Redo-SAVR and ViV-TAVI are both valuable strategies for failure of bioprosthetic aortic valves, with comparable results in terms of survival and adverse events when patients’ selection is solid. Yet, resulting PPM differs greatly after the two procedures and should be central in the patient allocation process.
2024
Outcomes and Patients Selection Criteria in Redo-Surgical Aortic Valve Replacement versus Valve-in-Valve Transcatheter Aortic Valve Implantation for Degenerated Bioprosthetic Valves: A Retrospective Single-Center Study.
BACKGROUND: Redo-Surgical Aortic Valve Replacement (Redo-SAVR) and Valve-in-Valve Transcatheter Aortic Valve Implantation (ViV-TAVI) are two primary strategies for managing failure of bioprosthetic aortic valves. This appears to be of increasing concern due to the growing use of bioprostheses, even in the youngest. ViV-TAVI has been associated with improved perioperative safety compared with Redo-SAVR, but long-term outcomes remain uncertain. We therefore conducted a retrospective single-center study to compare the outcomes of the two procedures at our Institution. METHODS: We included all patients treated for aortic surgical bioprosthesis dysfunction by either Redo-SAVR or ViV-TAVI between 2015 and 2025. The primary endpoint was 1, 3, 5 and 8-year all-cause mortality. Secondary endpoints were major adverse cardiovascular events (MACE) and cardiac re-hospitalization. Propensity score matching was performed to account for the non-randomized allocation of treatment, then Cox regression and Kaplan-Meier curves were used for both primary and secondary endpoints. RESULTS: 58 Redo-SAVR and 103 ViV-TAVI patients were included. VIV-TAVI patients were older, more comorbid and had higher STS-PROM scores, with an STS-PROM cut-off of 2.62% for mortality being the most discriminative parameter between the two groups. Even if survival and freedom from cardiac rehospitalization were significantly higher in Redo-SAVR in the unmatched analysis, the propensity-score-matched survival curves showed comparable survival during the first years of follow-up and a long-term survival advantage of Redo-SAVR emerging beyond 5.8 years (HR 1.31, 95%CI 0.61–2.82). Freedom from MACE and cardiac rehospitalization were comparable. Post-operative prosthesis-patient mismatch (PPM) was however found to be significantly higher in VIV-TAVI both in the unmatched (p < 0.001) and matched cohorts (p = 0.008). CONCLUSIONS: Redo-SAVR and ViV-TAVI are both valuable strategies for failure of bioprosthetic aortic valves, with comparable results in terms of survival and adverse events when patients’ selection is solid. Yet, resulting PPM differs greatly after the two procedures and should be central in the patient allocation process.
Redo-SAVR
ViV-TAVI
bioprosthetic valves
File in questo prodotto:
File Dimensione Formato  
Guerra_Giulia.pdf

Accesso riservato

Dimensione 1.27 MB
Formato Adobe PDF
1.27 MB Adobe PDF

The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.12608/120610